U.K. researchers are testing a new drug, AMG 319, which could be used to treat head and neck cancers.
AMG 319, initially developed as a leukemia drug by Amgen, will be used in phase II trials at several U.K. hospitals to examine its impact on patients with squamous cell carcinoma, according to Cancer Research UK. The experimental drug is designed to trigger an immune response by "switching off" certain types of white blood cells.